Back to Journals » Metalloproteinases In Medicine » Volume 3

Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine

Authors Mohan V, Talmi-Frank D, Arkadash V, Papo N, Sagi I

Received 12 January 2016

Accepted for publication 17 March 2016

Published 12 July 2016 Volume 2016:3 Pages 31—47

DOI https://doi.org/10.2147/MNM.S65143

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ajay Chaudhary

Peer reviewer comments 2

Editor who approved publication: Dr Yoshifumi Itoh

Vishnu Mohan,1 Dalit Talmi-Frank,1 Valeria Arkadash,2 Niv Papo,2 Irit Sagi1

1Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 2Department of Biotechnology Engineering, Faculty of Engineering Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Abstract: The development of therapeutic matrix metalloproteinase (MMP) inhibitors has evolved from broad-spectrum peptidomimetic inhibitors with deleterious side effects, to highly selective agents. These range from small molecules to antibodies, antisense inhibitors, and engineered N-terminal tissue inhibitors of metalloproteinase domain. The advances in inhibitor design along with promising new global molecular insights into MMP structures, the protease web, and the role of extracellular matrix in diseases have contributed toward a renewed interest in using MMPs as valid drug targets. This review aims to address the advances and challenges concerning the design, development, and current status of anti-MMP agents in this new era of post-broad-spectrum MMP inhibitors. Highly selective inhibitors of MMPs promise to usher in an era of specific targeting of diseased tissue proteolysis networks, with markedly reduced negative repercussions, and to uncover the molecular and mechanistic roles of MMP isoforms in cancer, inflammation, and infection.

Keywords:
matrix metalloproteinase inhibitors, MMPI, small molecules, MMP-inhibiting monoclonal antibodies, engineered N-TIMP, miRNA

A Letter to the Editor has been received and published for this article.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]